Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268400 | 1.00 | RAB9A (0.54) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL31408756 | 1.00 | RAB9A (0.54) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL1399139 | 0.89 | RAB9A (0.50) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL1399137 | 0.89 | RAB9A (0.50) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL10783189 | 0.88 | CA12 (0.59) | RAB9ANPC1ALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL28567920 | 0.88 | PTGS2 (0.50) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL28567922 | 0.88 | PTGS2 (0.50) | RAB9ACYP1A2NPC1ALDH1A1CYP2C19 | |
| SCHEMBL11054639 | 0.86 | CA12 (0.57) | RAB9ANPC1ALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL12610085 | 0.85 | ATM (0.53) | RAB9AALDH1A1SMN1; SMN2EGFRERBB2 | |
| SCHEMBL20201866 | 0.84 | MEN1 (0.51) | ALDH1A1SMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
| US-20120321533-A1 | CATALYST | ALMQVIST FREDRIK (SE) | 2012-12-20 | — | — | US | disclosed |
| US-20120321533-A1 | CATALYST | ALMQVIST FREDRIK (SE) | 2012-12-20 | — | — | US | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| US-20100119424-A1 | CATALYST | ALMQUEST AB (SE) | 2010-05-13 | — | — | US | disclosed |
| EP-1994983-A1 | Catalyst containing covalently bonded formate groups and Pd(0) and process for its obtention | Almquest AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-0987248-B1 | Amide derivatives and their therapeutic use | WELLCOME FOUND (GB) | 2002-09-04 | — | — | EP | disclosed |
| EP-0699180-B1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | WELLCOME FOUND (GB) | 2000-11-22 | — | — | EP | disclosed |
| US-6124284-A | REDUCED SIDE EFFECTS | GLAXO WELLCOME INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0987248-A1 | Amide derivatives and their therapeutic use | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-03-22 | — | — | EP | disclosed |
| US-5872118-A | RELAXATION OF SKELETAL MUSCLE IN SPASTIC, HYPERTONIC AND HYPERKINETIC CONDITIONS | GLAXO WELLCOME INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0699180-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026693-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0266725-A1 | 4-cyano-4-(fluorophenyl)-3-(substituted phenyl) butyric acids, esters and derivatives thereof, and a method of selectively controlling undesirable vegetation in rice therewith | AMERICAN CYANAMID COMPANY (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | RAB9A 2254/4885CYP1A2 1261/4885NPC1 1656/4885 |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | RAB9A 1336/4885CYP1A2 458/4885NPC1 1097/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | RAB9A 1727/4885CYP1A2 362/4885NPC1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.